Learning Objectives:

Upon completion of this activity, clinicians should be able to:

• Discuss the current management of taxane-resistant metastatic breast cancer
• Describe recent clinical trials involving newer taxanes [e.g., 130-nanometer albumin-bound paclitaxel (nab paclitaxel)] and newer chemotherapy (e.g., capecitabine)
• Describe recent clinical trials involving novel agents, e.g., epothilones, as monotherapy or in combination with capecitabine for the treatment of taxane-resistant, metastatic breast cancer, with emphasis on efficacy and safety
• Discuss the mechanisms of action of the various proposed new agents, as well as advances in understanding the biology and genetics of multi-drug resistance (MDR) in taxane-resistant metastatic breast cancer.

Accreditation Statement:

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through joint sponsorship of Albert Einstein College of Medicine and interMDnet Corporation. Albert Einstein College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation:

Albert Einstein College of Medicine designates this educational activity for a maximum of 9.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

To Obtain Credit, You Must:

Read the educational activity, complete the post-test, answer at least 70% of the post-test questions correctly and complete the activity evaulation. Certificates will be immediately available online for downloading and printing.